Inherited Genetics Steer Tumor Evolution After DNA Damage
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Cambridge researchers, co-led with the University of Edinburgh and institutions across Europe and the US, published a Nature study providing the first direct evidence that inherited genetic background steers how tumors develop after DNA damage.
- The team bred four mouse strains with differing liver-cancer susceptibility to approximate human population-level genetic diversity, then gave each mouse the same single dose of the carcinogen DEN at 15 days old under controlled conditions.
- Scientists sequenced the genomes of nearly 600 tumors and found cancers across all four strains converged on activating the MAPK signaling pathway, but the specific driver mutations that emerged varied with each mouse's inherited genetics.
- Certain genetic backgrounds showed a striking tendency toward whole-genome duplication — a full copying of the chromosome set — revealing that inherited DNA influences which molecular routes tumors take to reach the same biological endpoint.
- Co-leaders Professor Duncan Odom, Dr. Sarah Aitken, and Professor Martin Taylor said the findings indicate future cancer prevention, screening, and drug-response strategies will need to factor in inherited genetics and human population diversity.
- Cancer Research UK, the Medical Research Council, the European Research Council, and Wellcome funded the work, carried out primarily at the CRUK Cambridge Institute.
Why it matters: The study gives researchers a mechanistic explanation for why two people hit by the same carcinogen — for example, most smokers versus those who develop lung cancer without smoking — can face radically different outcomes. If the mouse-to-human translation holds, oncologists would have a concrete reason to stratify prevention and drug selection by inherited genetic background rather than treating cancer risk as uniform within an exposure group.
